There's Reason For Concern Over Blueprint Medicines Corporation's (NASDAQ:BPMC) Massive 28% Price Jump
May 04
Have your own idea? Try our Stock Screener
U.S. Biotech Industry Analysis
UpdatedMay 04, 2025
DataAggregated Company Financials
Companies570
- 7D2.8%
- 3M-4.2%
- 1Y-6.8%
- YTD-1.3%
The Biotech industry is up 2.8% in the last week, with AbbVie up 6.7%. However, the industry is down 6.8% over the past year. As for the next few years, earnings are expected to grow by 24% per annum.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Mon, 05 May 2025 | US$959.6b | US$153.8b | -US$24,601,947,084.66 | 19.7x | -39x | 6.2x |
| Wed, 02 Apr 2025 | US$796.3b | US$118.6b | -US$37,136,248,113.92 | 21.4x | -21.4x | 6.7x |
| Fri, 28 Feb 2025 | US$843.5b | US$118.6b | -US$37,303,235,811.02 | 17x | -22.6x | 7.1x |
| Sun, 26 Jan 2025 | US$981.2b | US$149.5b | -US$26,320,970,275.68 | 17.2x | -37.3x | 6.6x |
| Tue, 24 Dec 2024 | US$956.2b | US$149.9b | -US$26,388,997,522.19 | 15.3x | -36.2x | 6.4x |
| Thu, 21 Nov 2024 | US$989.6b | US$150.0b | -US$26,776,308,908.73 | 16.8x | -37x | 6.6x |
| Sat, 19 Oct 2024 | US$909.8b | US$113.1b | -US$35,980,542,500.02 | 21.7x | -25.3x | 8x |
| Mon, 16 Sep 2024 | US$932.2b | US$113.2b | -US$36,059,145,110.59 | 23.4x | -25.9x | 8.2x |
| Wed, 14 Aug 2024 | US$861.0b | US$113.0b | -US$36,639,604,267.04 | 22.7x | -23.5x | 7.6x |
| Fri, 12 Jul 2024 | US$1.2t | US$164.5b | -US$28,077,075,512.80 | 29.6x | -41.5x | 7.1x |
| Sun, 09 Jun 2024 | US$1.2t | US$164.5b | -US$26,798,622,131.21 | 28.1x | -43.1x | 7x |
| Tue, 07 May 2024 | US$1.1t | US$162.6b | -US$27,558,558,120.24 | 27.4x | -40.8x | 6.9x |
| Thu, 04 Apr 2024 | US$1.1t | US$164.3b | -US$23,560,093,353.12 | 23.5x | -48.7x | 7x |
| Sat, 02 Mar 2024 | US$1.2t | US$167.9b | -US$21,266,980,809.75 | 15.9x | -55.4x | 7x |
| Mon, 29 Jan 2024 | US$1.4t | US$204.7b | -US$22,652,938,045.00 | 18.3x | -63.1x | 7x |
| Wed, 27 Dec 2023 | US$1.4t | US$204.9b | -US$22,191,084,128.00 | 19.6x | -61.8x | 6.7x |
| Fri, 24 Nov 2023 | US$1.2t | US$204.7b | -US$22,047,730,821.00 | 18x | -55.3x | 6x |
| Sun, 22 Oct 2023 | US$1.2t | US$207.4b | -US$13,088,260,702.00 | 16.6x | -93.6x | 5.9x |
| Tue, 19 Sep 2023 | US$1.3t | US$207.5b | -US$12,859,693,014.00 | 17.2x | -99.5x | 6.2x |
| Thu, 17 Aug 2023 | US$1.3t | US$207.7b | -US$12,321,742,893.00 | 17.7x | -103.2x | 6.1x |
| Sat, 15 Jul 2023 | US$1.1t | US$186.7b | -US$15,944,193,566.00 | 13.3x | -71.2x | 6.1x |
| Mon, 12 Jun 2023 | US$1.1t | US$186.0b | -US$15,970,598,297.00 | 11.7x | -71.6x | 6.2x |
| Wed, 10 May 2023 | US$1.2t | US$192.6b | -US$11,459,990,654.00 | 14.5x | -101.7x | 6x |
| Fri, 07 Apr 2023 | US$1.2t | US$216.9b | -US$5,766,366,754.00 | 14.5x | -201.7x | 5.4x |
| Sun, 05 Mar 2023 | US$1.2t | US$199.0b | -US$4,964,241,359.00 | 16.5x | -232.2x | 5.8x |
| Tue, 31 Jan 2023 | US$1.2t | US$203.7b | US$1.7b | 14.6x | 660.8x | 5.7x |
| Thu, 29 Dec 2022 | US$1.1t | US$203.3b | US$1.6b | 14.2x | 689x | 5.5x |
| Sat, 26 Nov 2022 | US$1.1t | US$202.3b | US$1.3b | 14.6x | 845.6x | 5.6x |
| Mon, 24 Oct 2022 | US$1.1t | US$206.2b | US$5.3b | 15.8x | 200.9x | 5.2x |
| Wed, 21 Sep 2022 | US$1.1t | US$206.6b | US$5.8b | 14.4x | 180x | 5.1x |
| Fri, 19 Aug 2022 | US$1.1t | US$206.6b | US$7.3b | 16.2x | 148.6x | 5.3x |
| Sun, 17 Jul 2022 | US$1.1t | US$211.3b | US$10.6b | 17.2x | 102.8x | 5.2x |
| Tue, 14 Jun 2022 | US$917.5b | US$212.1b | US$10.9b | 14.2x | 84x | 4.3x |
| Thu, 12 May 2022 | US$938.1b | US$210.6b | US$12.5b | 12.8x | 75.3x | 4.5x |
Price to Earnings Ratio
75.3x
Current Industry PE
- Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 6.3x.
Past Earnings Growth
- Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
- Revenues have also declined 9.9% per year, which is driving profits down.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | 2.98% | |
| Healthcare | 0.32% | |
| Biotech | 2.76% | |
| Biotech | 2.76% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| ABBV AbbVie | US$198.47 | 6.7% +US$22.0b | 21.2% | PE84.5x | |
| SMMT Summit Therapeutics | US$27.90 | 18.9% +US$3.4b | 535.5% | PB60.2x | |
| VRTX Vertex Pharmaceuticals | US$501.15 | 1.5% +US$1.9b | 25.0% | PS11.7x | |
| EXAS Exact Sciences | US$51.55 | 13.4% +US$1.3b | -16.9% | PS3.4x | |
| ALNY Alnylam Pharmaceuticals | US$259.39 | 3.1% +US$1.3b | 70.3% | PS14.4x |
